BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2465953)

  • 1. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
    Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis].
    Hochhaus A; Mindner K; Ostermann G; Höche D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):765-70. PubMed ID: 1713878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
    Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
    Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
    Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
    Zuk E
    Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
    Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
    Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet membrane fatty acids in thrombocytosis due to myeloproliferative disorders.
    Leoncini G; Maresca M; Balestrero F; Benatti U; Armani U; Piana A
    Cell Biochem Funct; 1984 Jan; 2(1):23-5. PubMed ID: 6467512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Megakaryocytic myelosis--clinical aspects, morphology and platelet function].
    Hochhaus A; Höche D; Mindner K; Ostermann G; Meyer M
    Klin Wochenschr; 1989 Jan; 67(2):51-9. PubMed ID: 2921844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders.
    Cortelazzo S; Galli M; Castagna D; Viero P; de Gaetano G; Barbui T
    Thromb Haemost; 1988 Feb; 59(1):73-6. PubMed ID: 3129810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of platelet aggregation abnormalities in thrombocytosis after thrombocytopheresis.
    Fabris F; Belloni M; Casonato A; Randi M; Ongaro G; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):853-62. PubMed ID: 6176511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis.
    Walsh PN; Murphy S; Barry WE
    Thromb Haemost; 1977 Dec; 38(4):1085-96. PubMed ID: 579686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood platelet and "extra-platelet" serotonin in some myeloproliferative disorders.
    Culebras Poza JM; Launay JM; Briere J; Dreux C
    Biomedicine; 1977 Nov; 27(8):300-3. PubMed ID: 597565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders.
    Malpass TW; Savage B; Hanson SR; Slichter SJ; Harker LA
    J Lab Clin Med; 1984 Jun; 103(6):894-904. PubMed ID: 6233383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytosis: age dependent aetiology and analysis of platelet indices for differential diagnosis.
    Syed NN; Usman M; Khurshid M
    Indian J Pathol Microbiol; 2007 Jul; 50(3):628-33. PubMed ID: 17883167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet abnormalities in myeloproliferative disorders.
    Holme S; Murphy S
    Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.